JOP20210010A1 - بروتينات مخصصة ل baff و b7rp1 وإستخداماتها - Google Patents
بروتينات مخصصة ل baff و b7rp1 وإستخداماتهاInfo
- Publication number
- JOP20210010A1 JOP20210010A1 JOP/2021/0010A JOP20210010A JOP20210010A1 JO P20210010 A1 JOP20210010 A1 JO P20210010A1 JO P20210010 A JOP20210010 A JO P20210010A JO P20210010 A1 JOP20210010 A1 JO P20210010A1
- Authority
- JO
- Jordan
- Prior art keywords
- b7rp1
- baff
- proteins
- proteins specific
- specific
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
يتم في هذا الإختراع وصف بروتين ثنائي الإختصاص موجه ضد BAFF وB7RP1، أحماض نووية تشفر لتلك البروتينات، وطرق لعمل تلك البروتينات، وإستخدامات تلك البروتينات
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780260P | 2013-03-13 | 2013-03-13 | |
US201461942776P | 2014-02-21 | 2014-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20210010A1 true JOP20210010A1 (ar) | 2023-01-30 |
Family
ID=50483540
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2014/0087A JOP20140087B1 (ar) | 2013-03-13 | 2014-03-11 | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
JOP/2021/0010A JOP20210010A1 (ar) | 2013-03-13 | 2021-01-12 | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2014/0087A JOP20140087B1 (ar) | 2013-03-13 | 2014-03-11 | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
Country Status (36)
Country | Link |
---|---|
US (3) | US10421823B2 (ar) |
EP (3) | EP3456344B1 (ar) |
JP (2) | JP6523243B2 (ar) |
KR (2) | KR102218723B1 (ar) |
CN (2) | CN105324127B (ar) |
AP (1) | AP2015008768A0 (ar) |
AU (1) | AU2014244498B2 (ar) |
CA (1) | CA2904992C (ar) |
CL (1) | CL2015002600A1 (ar) |
CR (1) | CR20150544A (ar) |
CY (1) | CY1120569T1 (ar) |
DK (2) | DK2968491T3 (ar) |
EA (1) | EA035388B1 (ar) |
ES (2) | ES2687299T3 (ar) |
HK (1) | HK1218885A1 (ar) |
HR (2) | HRP20220884T1 (ar) |
HU (2) | HUE040169T2 (ar) |
IL (1) | IL241281B (ar) |
JO (2) | JOP20140087B1 (ar) |
LT (2) | LT3456344T (ar) |
MX (2) | MX369502B (ar) |
MY (2) | MY198370A (ar) |
NZ (2) | NZ711954A (ar) |
PE (1) | PE20151772A1 (ar) |
PH (1) | PH12015502074A1 (ar) |
PL (2) | PL2968491T3 (ar) |
PT (2) | PT2968491T (ar) |
RS (2) | RS63431B1 (ar) |
SG (1) | SG11201507208VA (ar) |
SI (2) | SI2968491T1 (ar) |
TN (1) | TN2015000414A1 (ar) |
TW (1) | TWI603978B (ar) |
UA (1) | UA120034C2 (ar) |
UY (1) | UY35396A (ar) |
WO (1) | WO2014159725A1 (ar) |
ZA (1) | ZA201506708B (ar) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2387546T3 (es) * | 2001-05-11 | 2012-09-25 | Amgen Inc. | Péptidos y moléculas relacionadas que se unen a TALL-1 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
ITUB20151014A1 (it) | 2015-05-27 | 2016-11-27 | Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro | Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi |
CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
WO2020027224A1 (ja) * | 2018-07-31 | 2020-02-06 | 国立大学法人東京大学 | 新たな結合特異性を抗体に付与する超汎用法 |
Family Cites Families (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US4970154A (en) | 1987-10-09 | 1990-11-13 | Baylor College Of Medicine | Method for inserting foreign genes into cells using pulsed radiofrequency |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US5580756A (en) | 1990-03-26 | 1996-12-03 | Bristol-Myers Squibb Co. | B7Ig fusion protein |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
EP0590076A4 (en) | 1991-06-14 | 1997-02-12 | Dnx Corp | Production of human hemoglobin in transgenic pigs |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
EP0802800B1 (en) | 1993-08-12 | 2002-06-12 | Neurotech S.A. | Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules |
US6268212B1 (en) | 1993-10-18 | 2001-07-31 | Amgen Inc. | Tissue specific transgene expression |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
DE4435919C1 (de) | 1994-10-07 | 1995-12-07 | Deutsches Krebsforsch | Zinkfinger-DNA, -Protein und ihre Verwendung |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP0832269A1 (en) | 1995-06-07 | 1998-04-01 | Baylor College Of Medicine | Nucleic acid transporters for delivery of nucleic acids into a cell |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
US5679559A (en) | 1996-07-03 | 1997-10-21 | University Of Utah Research Foundation | Cationic polymer and lipoprotein-containing system for gene delivery |
AU4474497A (en) | 1996-10-08 | 1998-05-05 | U-Bisys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
CA2665133A1 (en) | 1996-10-25 | 1998-05-07 | Human Genome Sciences, Inc. | Neutrokine .alpha. |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
WO1998027114A2 (en) | 1996-12-17 | 1998-06-25 | Schering Corporation | Mammalian cell surface antigens; related reagents |
JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
IL133315A0 (en) | 1997-06-06 | 2001-04-30 | Regeneron Pharma | Ntn-2 member of tnf ligand family |
CA2292899A1 (en) | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
CA2303424A1 (en) | 1997-09-12 | 1999-03-18 | Jurg Tschopp | Kay - a novel immune system protein |
DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
AU752433B2 (en) | 1997-09-23 | 2002-09-19 | Bundesrepublik Deutschland letzvertreten durch Den Direktor des Robert-Koch-Instituts | Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use |
AU2212299A (en) | 1998-01-05 | 1999-07-26 | Genentech Inc. | Compositions and methods for the treatment of tumor |
WO1999062951A1 (en) | 1998-06-04 | 1999-12-09 | Shanghai Second Medical University | A human zinc finger protein gene (bmzf3) |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1141274B2 (en) | 1999-01-07 | 2014-11-12 | ZymoGenetics, Inc. | Soluble receptor br43x2 and methods of using them for therapy |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
MXPA01007464A (es) | 1999-01-25 | 2003-06-06 | Apoxis Sa | Baff, inhibidores del mismo y su uso en la modulacion de la respuesta de celula b. |
US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
US7435796B1 (en) | 1999-02-03 | 2008-10-14 | Amgen Inc. | Antibodies which bind B7RP1 |
US7708993B2 (en) | 1999-02-03 | 2010-05-04 | Amgen Inc. | Polypeptides involved in immune response |
HUP0105337A3 (en) | 1999-02-03 | 2011-01-28 | Amgen Inc | Polypeptides involved in immune response |
AU2880400A (en) | 1999-02-12 | 2000-08-29 | Amgen, Inc. | Tnf-related proteins |
CZ303725B6 (cs) | 1999-03-25 | 2013-04-03 | Abbott Gmbh & Co. Kg | Lidské protilátky, které se vází na lidský IL-12 a zpusoby jejich produkce |
US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
WO2000068378A1 (en) | 1999-05-06 | 2000-11-16 | National Jewish Medical And Research Center | Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof |
IL147270A0 (en) | 1999-07-02 | 2002-08-14 | Genentech Inc | Fusion peptides comprising a peptide ligand domain and a multimerization domain |
DE60037896D1 (de) | 1999-07-29 | 2008-03-13 | Medarex Inc | Menschliche antikörper gegen her2/neu |
WO2001012658A2 (en) | 1999-08-11 | 2001-02-22 | Isis Innovations Limited | Human icos ligand and application thereof |
CA2381770C (en) | 1999-08-24 | 2007-08-07 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
AU7599500A (en) | 1999-09-21 | 2001-04-24 | Genetics Institute Inc. | Novel gl50 molecules and uses therefor |
EP1900816A3 (en) | 1999-09-21 | 2008-03-26 | Genetics Institute, LLC | GL50 molecules and uses therefor |
CA2400214A1 (en) | 2000-02-11 | 2001-11-15 | Amgen Inc. | Fusion receptor from tnf family |
WO2001064704A1 (en) | 2000-03-02 | 2001-09-07 | Mayo Foundation For Medical Education And Research | hB7-H2, A NOVEL CO-STIMULATORY MOLECULE |
PT2281843T (pt) | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
GB0016633D0 (en) | 2000-07-07 | 2000-08-23 | Bp Exploration Operating | Process |
US6635750B1 (en) | 2000-07-20 | 2003-10-21 | Millennium Pharmaceuticals, Inc. | B7-H2 nucleic acids, members of the B7 family |
US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
EP2267018A3 (en) | 2000-08-18 | 2011-04-20 | Human Genome Sciences, Inc. | Binding polypeptides for B lymphocyte stimulator protein (BLyS) |
AU2002217969B2 (en) | 2000-11-28 | 2007-12-20 | Amgen Canada Inc. | Polypeptides involved in immune response |
US20040043457A1 (en) | 2001-01-18 | 2004-03-04 | Silke Schumacher | Bifunctional fusion proteins with glucocerebrosidase activity |
ES2387546T3 (es) | 2001-05-11 | 2012-09-25 | Amgen Inc. | Péptidos y moléculas relacionadas que se unen a TALL-1 |
AR035119A1 (es) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
WO2004043989A2 (en) | 2002-11-07 | 2004-05-27 | Medarex, Inc. | Human monoclonal antibodies to heparanase |
RU2366664C2 (ru) * | 2002-12-17 | 2009-09-10 | Мерк Патент Гмбх | Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2 |
WO2004060911A2 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
DK1629011T3 (da) | 2003-05-31 | 2010-05-03 | Micromet Ag | Humane anti-humane-DC3-bindingsmolekyler |
US7271245B2 (en) | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
JPWO2006003999A1 (ja) | 2004-07-05 | 2008-07-31 | 財団法人化学及血清療法研究所 | ヒト抗ヒトb7rp−1抗体およびその抗体フラグメント |
WO2006010057A2 (en) * | 2004-07-08 | 2006-01-26 | Amgen Inc. | Therapeutic peptides |
AU2005289685B2 (en) * | 2004-09-24 | 2009-07-16 | Amgen Inc. | Modified Fc molecules |
EP1915398B1 (en) | 2005-07-18 | 2016-04-20 | Amgen Inc. | Human anti-b7rp1 neutralizing antibodies |
CA2618482C (en) | 2005-08-19 | 2014-10-07 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
PE20070684A1 (es) | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
EA030313B1 (ru) | 2007-03-27 | 2018-07-31 | Займодженетикс, Инк. | СПОСОБ СНИЖЕНИЯ УРОВНЕЙ IgM, IgG И IgA У МЛЕКОПИТАЮЩИХ И КОМПОЗИЦИЯ ДЛЯ ОСУЩЕСТВЛЕНИЯ ЭТОГО СПОСОБА |
US20090022720A1 (en) | 2007-07-20 | 2009-01-22 | Stephan Fischer | Conjugate of an antibody against CD4 and antifusogenic peptides |
WO2009015345A1 (en) * | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
WO2009052293A1 (en) | 2007-10-16 | 2009-04-23 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
EP2072527A1 (en) * | 2007-12-21 | 2009-06-24 | Altonabiotec AG | Fusion polypeptides comprising a SHBG dimerization component and uses thereof |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
NZ586701A (en) | 2008-01-03 | 2013-07-26 | Scripps Research Inst | Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2) |
JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法 |
FR2944448B1 (fr) | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
ES2704038T3 (es) | 2011-05-24 | 2019-03-13 | Zyngenia Inc | Complejos multiespecíficos multivalentes y monovalentes y sus usos |
AR090626A1 (es) | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
US9458246B2 (en) * | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
BR112015023752B1 (pt) | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo |
BR112016014731A2 (pt) | 2014-01-31 | 2017-09-19 | Boehringer Ingelheim Int | Anticorpos anti-baff |
-
2014
- 2014-03-11 JO JOP/2014/0087A patent/JOP20140087B1/ar active
- 2014-03-12 UA UAA201508877A patent/UA120034C2/uk unknown
- 2014-03-12 EP EP18182864.1A patent/EP3456344B1/en active Active
- 2014-03-12 TW TW103108956A patent/TWI603978B/zh active
- 2014-03-12 PT PT14717310T patent/PT2968491T/pt unknown
- 2014-03-12 EP EP20158997.5A patent/EP3689371A1/en active Pending
- 2014-03-12 PL PL14717310T patent/PL2968491T3/pl unknown
- 2014-03-12 US US14/776,399 patent/US10421823B2/en active Active
- 2014-03-12 DK DK14717310.8T patent/DK2968491T3/en active
- 2014-03-12 NZ NZ711954A patent/NZ711954A/en unknown
- 2014-03-12 WO PCT/US2014/024908 patent/WO2014159725A1/en active Application Filing
- 2014-03-12 HR HRP20220884TT patent/HRP20220884T1/hr unknown
- 2014-03-12 CN CN201480020434.6A patent/CN105324127B/zh active Active
- 2014-03-12 MY MYPI2018002384A patent/MY198370A/en unknown
- 2014-03-12 MY MYPI2015703088A patent/MY171938A/en unknown
- 2014-03-12 RS RS20220711A patent/RS63431B1/sr unknown
- 2014-03-12 KR KR1020157027042A patent/KR102218723B1/ko active IP Right Grant
- 2014-03-12 PL PL18182864.1T patent/PL3456344T3/pl unknown
- 2014-03-12 PT PT181828641T patent/PT3456344T/pt unknown
- 2014-03-12 ES ES14717310.8T patent/ES2687299T3/es active Active
- 2014-03-12 ES ES18182864T patent/ES2923909T3/es active Active
- 2014-03-12 AP AP2015008768A patent/AP2015008768A0/xx unknown
- 2014-03-12 KR KR1020217004604A patent/KR102361632B1/ko active IP Right Grant
- 2014-03-12 JP JP2016501678A patent/JP6523243B2/ja active Active
- 2014-03-12 HU HUE14717310A patent/HUE040169T2/hu unknown
- 2014-03-12 UY UY0001035396A patent/UY35396A/es active IP Right Grant
- 2014-03-12 SI SI201430908T patent/SI2968491T1/sl unknown
- 2014-03-12 MX MX2015012440A patent/MX369502B/es active IP Right Grant
- 2014-03-12 EA EA201591720A patent/EA035388B1/ru unknown
- 2014-03-12 AU AU2014244498A patent/AU2014244498B2/en active Active
- 2014-03-12 NZ NZ751502A patent/NZ751502A/en unknown
- 2014-03-12 LT LTEP18182864.1T patent/LT3456344T/lt unknown
- 2014-03-12 RS RS20181088A patent/RS57689B1/sr unknown
- 2014-03-12 CA CA2904992A patent/CA2904992C/en active Active
- 2014-03-12 HU HUE18182864A patent/HUE059507T2/hu unknown
- 2014-03-12 SG SG11201507208VA patent/SG11201507208VA/en unknown
- 2014-03-12 DK DK18182864.1T patent/DK3456344T3/da active
- 2014-03-12 LT LTEP14717310.8T patent/LT2968491T/lt unknown
- 2014-03-12 PE PE2015001973A patent/PE20151772A1/es unknown
- 2014-03-12 CN CN201910521740.2A patent/CN110437336A/zh active Pending
- 2014-03-12 EP EP14717310.8A patent/EP2968491B1/en active Active
- 2014-03-12 SI SI201431972T patent/SI3456344T1/sl unknown
-
2015
- 2015-09-07 IL IL241281A patent/IL241281B/en active IP Right Grant
- 2015-09-10 ZA ZA2015/06708A patent/ZA201506708B/en unknown
- 2015-09-11 MX MX2019013442A patent/MX2019013442A/es unknown
- 2015-09-11 TN TN2015000414A patent/TN2015000414A1/en unknown
- 2015-09-11 CL CL2015002600A patent/CL2015002600A1/es unknown
- 2015-09-11 PH PH12015502074A patent/PH12015502074A1/en unknown
- 2015-10-13 CR CR20150544A patent/CR20150544A/es unknown
-
2016
- 2016-06-17 HK HK16106993.6A patent/HK1218885A1/zh unknown
-
2018
- 2018-08-09 CY CY20181100835T patent/CY1120569T1/el unknown
- 2018-10-10 HR HRP20181629TT patent/HRP20181629T1/hr unknown
-
2019
- 2019-04-25 JP JP2019084291A patent/JP6825033B2/ja active Active
- 2019-09-23 US US16/579,321 patent/US11492417B2/en active Active
-
2021
- 2021-01-12 JO JOP/2021/0010A patent/JOP20210010A1/ar unknown
-
2022
- 2022-09-28 US US17/936,062 patent/US20230128444A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20210010A1 (ar) | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها | |
PH12016501763A1 (en) | Multispecific antibodies | |
HK1217499A1 (zh) | 蛋白的多聚形式 | |
MX2015013901A (es) | Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos. | |
MX2016016886A (es) | Anticuerpos anti-axl. | |
MX2017007941A (es) | Anticuerpos antagonistas anti-axl. | |
MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
MX2016016883A (es) | Anticuerpo anti-axl. | |
WO2014197885A3 (en) | Inhibitors of complement factor h | |
EA201600026A1 (ru) | Бактериальная гиалуронидаза и способ ее производства | |
IN2013MU00848A (ar) | ||
TW201612191A (en) | RSV-specific antibodies and functional parts thereof | |
BR112014027219A2 (pt) | método | |
AR097668A1 (es) | Colorante-polímero | |
EA201690942A1 (ru) | Антитела к ccl17 | |
CL2016001488A1 (es) | Quinazolin-thf-aminas como inhibidores de pde1 | |
IL258981A (en) | Methods for the production of proteins | |
IL241779A0 (en) | Method for protein production | |
AU350360S (en) | Filtration components | |
EA201692246A1 (ru) | Способ получения 2,6-диметилбензохинона | |
BR112015025165A2 (pt) | veículo | |
MX2016004573A (es) | Inhibidores de nsp4 y metodos de uso. | |
MX2015010789A (es) | Anticuerpos anti-pcsm. | |
MY179202A (en) | Method for producing specific ?,b-unsaturated aldehydes | |
TN2013000364A1 (fr) | تصميم جديد لطائرة مدنية ذات مقعد واحد و انظمة سلامة متطورة |